Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Everything Worth Reading.
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference
GlobeNewswire, Inc.
·
June 5, 2025
Geneva, Switzerland, June 5, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that...
Ultrafast neuromorphic computing driven by polariton nonlinearities
EIN Presswire
·
June 6, 2025
GA, UNITED STATES, June 6, 2025 /EINPresswire.com/ -- Neuromorphic computing, inspired by the human brain, offers a path to faster and more efficient AI. In a pioneering breakthrough, Chinese scientists demonstrate the first use of perovskite...
Proteomics International Laboratories Ltd (PIQ.AX) A Landmark in Non-Invasive Esophageal Cancer Diagnosis
ABN Newswire
·
June 4, 2025
A landmark in non-invasive Esophageal Cancer diagnosis - new PromarkerEso blood test clinical validation results published Perth, June 5, 2025 AEST (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ) (PIQLF:OTCMKTS), a pioneer in...
Memories of MK-ULTRA: A Riveting and Disturbing Tale of Trauma, Mind Control, and Survival
EIN Presswire
·
June 4, 2025
CLAYTON, CA, UNITED STATES, June 4, 2025 /EINPresswire.com/ -- Bill Yarborough’s Memories of MK-ULTRA is a haunting, semi-autobiographical novel inspired by the infamous CIA mind control experiments conducted under the MK-ULTRA program in the...
Neurofibromatosis Type 1 (NF1) Drug Development Gains Momentum Amid Growing Need for Safer, More Effective Therapies
EIN Presswire
·
June 3, 2025
NF1 drug development accelerates with novel treatments aiming to surpass current MEK inhibitors in efficacy, safety, and patient-friendly delivery. AUSTIN, TX, UNITED STATES, June 3, 2025 /EINPresswire.com/ -- In the realm of rare genetic...
Special Edition of Mary Alcock’s A Day Between Destinies Launches This Season
EIN Presswire
·
June 4, 2025
DALLAS, TX, UNITED STATES, June 4, 2025 /EINPresswire.com/ -- Special Edition of Mary Alcock’s A Day Between Destinies to Launch This Season A story that began on a train ride returns with new material, deeper reflections, and a closer look at...
Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering
GlobeNewswire, Inc.
·
June 5, 2025
NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits,...
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
GlobeNewswire, Inc.
·
June 6, 2025
NEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight...
'Moonfall: The Sefer Ha’llham’s Prophecy' –A Dazzling Fantasy Debut
EIN Presswire
·
June 4, 2025
NEW YORK, NY, UNITED STATES, June 4, 2025 /EINPresswire.com/ -- Charles J. Lewis IV Unveils His Spellbinding Fantasy Novel – Moonfall: The Sefer Ha’llham’s Prophecy Charles J. Lewis IV, a visionary storyteller hailing from the gritty streets of...
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
GlobeNewswire, Inc.
·
June 6, 2025
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today...
Breaking Barriers in Niemann-Pick Type C – A New Era of Hope for an Ultra-Rare Disorder | Competitive Intelligence
EIN Presswire
·
June 6, 2025
NPC’s treatment landscape is changing fast, with new FDA approvals and a promising pipeline shaping hope for this ultra-rare neurological disorder. AUSTIN, TX, UNITED STATES, June 6, 2025 /EINPresswire.com/ -- Niemann-Pick Type C (NPC), once a...
Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
GlobeNewswire, Inc.
·
June 6, 2025
Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate (PPi) efflux via on-target engagement of the...
From Carnegie Hall to Columbia: Why an Acclaimed Artist With 4 Degrees Went Back to School—In a Room Full of Gen Zers
EIN Presswire
·
June 4, 2025
Georgia Shreve reenters the classroom with a lifetime of creation behind her—and curiosity still ahead. NEW YORK, NY, UNITED STATES, June 4, 2025 /EINPresswire.com/ -- Georgia Shreve, a composer, author, and interdisciplinary artist whose work...
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
GlobeNewswire, Inc.
·
June 4, 2025
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health market Evaluation of AZD5658 expands...
New Family Film from Jae Huff to Hit Theaters Summer 2025
EIN Presswire
·
June 4, 2025
A Modern, Feel-Good Mystery Adventure Aimed at Families Everywhere NASHVILLE, TN, UNITED STATES, June 4, 2025 /EINPresswire.com/ -- Get ready to laugh, feel, and be inspired—independent filmmaker and Huff Media Productions CEO Jae Huff is...
Catalyst OrthoScience Announces 5-8 Year Data Reporting Significant Functional Improvement and Pain Reduction for Anatomic Total Shoulder Arthroplasty
Business Wire
·
June 4, 2025
Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the orthopedics market, today announced positive, mid-term data reporting on patients treated with its...
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
GlobeNewswire, Inc.
·
June 4, 2025
Designation Supported by CLOVER WaM Phase 2 Study Data Which Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for Fast-Track, Conditional Marketing...
E. A. Reining Debuts Poetic Masterpiece 'From the Ocean to the Stars'
EIN Presswire
·
June 2, 2025
A soulful collection guiding readers through loss, healing, and self-discovery CA, UNITED STATES, June 2, 2025 /EINPresswire.com/ -- Emerging author E. A. Reining invites readers on an emotional and transformative journey in her debut poetry...
Biomarker Market is expected to generate a revenue of USD 130.16 Billion by 2032, Globally, at 13.77% CAGR: Verified Market Research®
GlobeNewswire, Inc.
·
June 4, 2025
Lewes, Delaware, June 04, 2025 (GLOBE NEWSWIRE) -- The Global Biomarker Market Size is projected to grow at a CAGR of 13.77% from 2026 to 2032, according to a new report published by Verified Market Research®. The report reveals that the market...
RAD 2025: Long-Term Data on Nemluvio® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to Two Years
Business Wire
·
June 6, 2025
Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio in moderate-to-severe atopic dermatitis. The data show that Nemluvio is well tolerated,...